Imatinib is a highly selective inhibitor of tyrosine kinase used in the treatment of CML and GIST. However, the cost of the drug is prohibitive especially in the developing countries. The aim of this study is to compare pharmacokinetics profile of a new Imatinib generic formulation (Imatinib tablets 400mg batch number: 2090602, Hikma Pharmaceuticals PLC) with those of Glivec, (batch number: S0143, Novartis Pharma AG, Basle, Switzerland) in healthy male volunteers /fed state. The study was single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover design. The study was performed by CRO Algorithme Pharma Inc, (Quebec, Canada) in accordance with Good Clinical Practices and the applicable regulatory requirements. Male volunteers, non-or ex-smokers, of at least 18 years of age but not older than 55 years with a body mass index (BMI) greater than or equal to 18.5 and below 30 kg/m2 were selected according to the inclusion and exclusion criteria. In each study period, a single 400 mg dose of Imatinib was orally administered with about 240 mL of water in the morning after a 10-hour overnight fast, thirty (30) minutes after the start of a high-fat, high-calorie breakfast. Subjects remained seated for at least the first 4 hours following each drug administration. In each study period, twenty (20) blood samples were collected by venipuncture in pre-cooled Vacutainers containing EDTA. The first blood sample (2 x 4 mL) was collected prior to drug administration while the others (1 x 4 mL each) were collected at 1, 1.5, 2, 2. 33, 2.67, 3, 3.33, 3.67, 4, 4.5, 5, 6, 8, 10, 14, 18, 24, 48 and 72 hours post drug administration. The drug administrations were separated by at least 14 calendar days. Urine drug and ethyl alcohol screening was performed before each period of the study. Hematology and biochemistry tests were repeated after the collection of the last blood sample of the study. Safety was evaluated through the assessment of adverse events, and laboratory tests. Imatinib plasma samples were analyzed employing a validated HPLC method using MS/MS detection. For a 400 mg dose of Imatinib, the analytical range was approximately 10 ng/mL to 4000 ng/mL. Descriptive statistics were used to summarize adverse events, safety results and demographic variables (age, height, weight and BMI). The main pharmacokinetic parameters of interest for this study were C max , AUC 0-T and AUC 0-∞ . Other parameters such as T max , AUC T/∞ , K el and T 1/2el were provided for information purposes only. The natural logarithmic transformation of C max , AUC 0-T and AUC 0-∞ was used for all statistical inference. The mean (C.V. %) of C max , T max , AUC 0-T and AUC 0-∞ ( for Imatinib were 1760.5 ng/ml (26.6%), 3.67 hrs (26.4%), 30946.5 ng.h/ml (28.0%) and 31912.5 ng.h/ml (28.2%) versus 1779.4 ng/ ml (25.8%), 3.67 hrs (39.0%), 31073.6 ng.h/ml (25.7%) and 32270.9 ng.h/ml (26.4%) for Glivec. The 90% confidence intervals of C max , AUC 0-T and AUC 0-∞ for Imatinib 400 mg were (92.00%-105.52%), (95.69%-102.31%) ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.